Athena Partner has received Ondansetron ODT approval in UK
Athena DDS, a technology driven company specialized in Oral Solid Dosage forms, further strengthens
its roots in UK market obtaining Marketing Approval for Ondansetron 4 & 8 mg ODT.
Alexandre Williams, Managing director of Athena DDS ‘looks forward for a prosperous future with
second approval in UK for Ondansetron 4 & 8 mg ODT. With every such achievement Athena is
focused, demonstrating our company’s ability to work successfully in the developed markets; thereby
extending our footprint and embracing new opportunities.’
Ondansetron is used alone or with other medications to prevent nausea and vomiting caused by cancer drug
treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after
For more information, please contact:
About Athena DDS:
Athena with its EU GMP approved facility and state of art R&D Centre is focused on the innovative and
value-added products in mature and emerging markets and is engaged in Licensing and Development model
for Specialty Pharma, Multinationals and other established companies. Athena provides comprehensive
product lifecycle management solutions for Oral Solids based on its proprietary technology platforms.
Athena has already developed many innovative products CTD format viz., Domperidone ODT, Fenofibrate
Capsule, Levocetirizine ODT, Meloxicam ODT, Metformin SR Tablets, Ondansetron ODT, Secnidazole
High Dose Sachet as one-shot treatment, Racecadotril Sachets, Tramadol Paracetamol ODT & Tablet,
Voglibose ODT and Zolpidem ODT & SL ODT. These products are already marketed by leading companies
across geographies or are under registration.
For further information, please visit www.athenadds.com